Expression Patterns of Glucose Transporter-1 Gene and Thyroid Specific Genes in Human Papillary Thyroid Carcinoma

Purpose

The expression of glucose transporter-1 (Glut-1) gene and those of major thyroid-specific genes were examined in papillary carcinoma tissues, and the expressions of these genes were compared with cancer differentiation grades.

Materials and Methods

Twenty-four human papillary carcinoma tissues were included in this study. The expressions of Glut-1- and thyroid-specific genes [sodium/iodide symporter (NIS), thyroid peroxidase, thyroglobulin, TSH receptor and pendrin] were analyzed by RT-PCR. Expression levels were expressed as ratios versus the expression of beta-actin. Pathologic differentiation of papillary carcinoma was classified into a relatively well-differentiated group (n = 13) and relatively less differentiated group (n = 11).

Results

Glut-1 gene expression was significantly higher in the less differentiated group (0.66 ± 0.04) than in the well-differentiated group (0.59 ± 0.07). The expression levels of the NIS, PD and TG genes were significantly higher in the well-differentiated group (NIS: 0.67 ± 0.20, PD: 0.65 ± 0.21, TG: 0.74 ± 0.16) than in the less differentiated group (NIS: 0.36 ± 0.05, PD: 0.49 ± 0.08, TG: 0.60 ± 0.11), respectively. A significant negative correlation was found between Glut-1 and NIS expression, and positive correlations were found between NIS and TG, and between NIS and PD.

Conclusion

The NIS, PD and TG genes were highly expressed in well-differentiated thyroid carcinomas, whereas the Glut-1 gene was highly expressed in less differentiated thyroid carcinomas. These findings provide a molecular rationale for the management of papillary carcinoma, especially in the selection of FDG PET or radioiodine whole-body scan and I-131-based therapy.     

Intratumoral Heterogeneous F-18 Fluorodeoxyglucose Uptake Corresponds with Glucose Transporter-1 and Ki-67 Expression in a Case of Krukenberg Tumor: Localization of Intratumoral Hypermetabolic Focus by Fused PET/MR Image

The expression of glucose transporters (Glut-1, Glut-3), hexokinase-II, and Ki-67 has been proposed to explain intratumoral heterogeneous F-18 fluorodeoxyglucose (FDG) uptake. We report a case of Krukenberg tumor with intratumoral heterogeneous FDG uptake which corresponded well with the expression levels of Glut-1 and ki-67. Fused positron emission tomography (PET)/magnetic resonance (MR) imaging was helpful for localizing the metabolically active area in the tumor specimen. This report elucidates the relationship between the intratumoral heterogeneous FDG uptake and biologic heterogeneity, and shows the usefulness of PET/MR in research on intratumoral heterogeneity.     

64排螺旋CT对胃印戒细胞癌淋巴结转移的诊断价值

目的：评价64排螺旋CT对胃印戒细胞癌淋巴结转移的诊断价值。方法：回顾性分析总结40例胃印戒细胞癌患者的CT平扫及三期动态增强扫描资料,并与手术病理结果对照。结果：本组病例术后淋巴结转移情况为N0期16例,N2期6例,N3期为11例,CT以淋巴结长径〉6mm为阳性标准,发现NO期16例、N1期7例、N2期5例及N3期4例,其中CT各N分期特异性在76．5％-94．7％之间,但是对N2及N3分期的敏感性欠佳（分别为28．6％和33．3％）。转移淋巴结特点为静脉期和延迟期强化明显,虽高于动脉期强化,但是之间无统计学意义上的差异（P〉0．05）。结论：64排螺旋CT对胃印戒细胞癌转移淋巴结的诊断及N分期有帮助,其诊断特异性较高,但是准确性和敏感性均有待提高。     

鼻咽癌组织~(18)F-FDG摄取与Glut-1和VEGF表达关系研究

目的: 探讨鼻咽癌的18F-FDG摄取与肿瘤组织葡萄糖易化扩散转运蛋白及血管内皮细胞生长因子表达的关系.材料和方法:对40例鼻咽癌患者进行正电子发射体层显像(PET)检查,测定肿瘤最大摄取值(SUVmax);应用标准链霉菌抗生物素蛋白-过氧化物酶亲和(SP)免疫组化法检测40例患者肿瘤组织葡萄糖易化扩散转运蛋白1(Glut-1)和血管内皮细胞生长因子(VEGF)的表达.结果:40例鼻咽癌组织的SUVmax为9.45±1.87;40例鼻咽癌组织Glut-1阳性细胞率为45.18%,VEGF染色阳性细胞率为60.8%;鼻咽癌组织18F-FDG摄取(SUVmax)与Glut-1表达阳性率分级相关(r=0.369,P=0.019),鼻咽癌组织18F-FDG摄取(SUVmax)与VEGF表达阳性率分级相关(r=0.460,P=0.03).结论:鼻咽癌组织18F-FDG摄取与Glut-1和VEGF过度表达相关.     

胃癌螺旋CT与病理、nm23-H1蛋白表达的相关性研究

目的 探讨胃癌螺旋CT征象与手术病理及nm23-H1蛋白表达间的关系.资料与方法 对65例胃癌行低张力水充盈螺旋CT三期增强扫描,所有病例均行手术切除,术后标本采用免疫组织化学SP法检测肿瘤组织中nm23-H1蛋白表达.将螺旋CT诊断结果 与病理结果 、nm23-H1蛋白表达进行对照.结果 65例胃癌TNM分期CT的准确性为80.0%(52/65),nm23-H1蛋白阳性表达率为50.8%(33/65).CT像上的病灶大小、浆膜侵犯、淋巴结转移、TNM分期与病理结果 一致性良好,与nm23-H1蛋白阳性表达率均密切相关(P＜0.05).结论 螺旋CT可较准确地反映胃癌增殖、浸润转移的病理学及生物学特性.     

Impact of Lymphoid Follicles and Histiocytes on the False-Positive FDG Uptake of Lymph Nodes in Non-Small Cell Lung Cancer

Purpose

Although ¹⁸F-fluorodeoxyglucose (FDG) PET/CT has improved the accuracy of evaluating lymph node (LN) staging in non-small cell lung cancer (NSCLC), false-positive results remain a problem. The reason why benign LNs show high FDG uptake is still unclear. The aim of this study was to identify molecular and pathological characteristics of benign LNs showing high FDG uptake.

Materials and Methods

We studied 108 mediastinal LNs of pathologically benign nature obtained from 43 patients with NSCLC who underwent FDG PET/CT and surgery. We measured the following parameters in each LN: maximum standardized uptake value (maxSUV), short diameter, maximum Hounsfield unit (maxHU) value, occupied proportions of lymphoid follicles, histiocytes in extrafollicular space and the degree of glucose transporter 1 (Glut1) expression. We compared the parameters between two LN groups according to maxSUV.

Results

There were 74 LNs showing maxSUV≥3.0 (group 1) and 34 LNs with maxSUV<3.0 (group 2). The size of LN (p < 0.001) and maxHU (p = 0.003) in group 1 was higher than that in group 2. Histologically, the occupied proportions of lymphoid follicles (p = 0.031) or histiocytes (p = 0.004) were higher in group 1. The Glut1 expression of lymphoid follicles (p = 0.035) or histiocytes (p = 0.005) was also higher in group 1.

Conclusion

Lymphoid follicular hyperplasia and histiocyte infiltration associated with Glut1 overexpression are important molecular and pathological mechanisms for false-positive FDG uptake in benign mediastinal LNs in patients with NSCLC.     

Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study

Purpose

The clinical availability of 2-deoxy-2-[18F] fluoro-D-glucose (FDG) dual-time point positron emission tomography/computerized tomography (DTPP) has been investigated in diverse oncologic fields. The aim of this preliminary study was to evaluate the relationship between various immunohistopathologic markers reflecting disease progression of colorectal cancer and parameters extracted from FDG DTPP in colorectal cancer patients.

Materials and Methods

Forty-seven patients with histologically confirmed colorectal cancer were analyzed in this preliminary study. FDG DTPP consisted of an early scan 1 h after FDG injection and a delayed scan 1.5 h after the early scan. Based on an analysis of FDG DTPP, we estimated the maximum standardized uptake value (SUV) of tumors on the early and delayed scans (SUV_early and SUV_delayed, respectively). The retention index (RI) was calculated as follows: (SUV_delayed - SUV_early) × 100/ SUV_early. The clinicopathological findings (size and T and N stages) and immunohistochemical factors [glucose transporter 1 (GLUT-1), hexokinase 2 (HK-2), p53, P504S, and β-catenin] were analyzed by visual analysis.

Results

The RIs calculated from the SUVs ranged from -1.8 to 73.4 (31.8 ± 15.5). The RIs were significantly higher in patients with high T stages (T3 and T4) than with low T stages (T1 and T2; p < 0.05). Among the immunohistochemical analytic markers, GLUT-1 had the highest positive staining rate (93.6%) compared to other markers. Based on univariable analysis, it was shown that the RI of high-level GLUT-1 expression was significantly higher than low-level GLUT-1 expression (p = 0.01), and the RI of high-level p53 expression was slightly higher than low-level p53 expression (p = 0.08). Multivariate analysis to investigate a link between RI and clinicopathologic parameters of colorectal carcinoma showed that GLUT-1, p53, and T staging were independently connected with increased RIs (p < 0.05, total) using backward selection methods. There was no significant statistical relationship between SUV_early and SUV_delayed and clinicopathologic parameters in this study.

Conclusion

The RIs obtained from preoperative colorectal cancers had a significant relationship to tumor size, T staging, GLUT-1, and p53, in contrast to SUV_early or SUV_delayed. Compared with previous reports, our results showed that RI can better predict GLUT-1 expression than HK-2 and other immunohistochemical markers. This study demonstrated that the RI might have the potential to be applied as a prognostic marker in preoperative colorectal cancer.     

Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study

Increased expression of glucose transporter-1 (Glut-1) and glucose transporter-3 (Glut-3) has been reported in many human cancers. The mechanism of glucose entry into oral squamous cell carcinoma (OSCC) remains unclear. In this study we investigated, in untreated human OSCC, the relationship between tumour fluorine-18 fluoro-2-deoxy-d-glucose (FDG) accumulation and the expression of Glut-1 and Glut-3, as well as the association between the expression of Glut-1 and of Glut-3. All patients underwent FDG positron emission tomography (PET) pre-operatively. Standardised uptake values (SUVs) were used for evaluation of tumour FDG uptake. Final diagnoses were established by histology. Immunohistochemical staining results were evaluated according to the percentage (%) of positive area, intensity and staining score. Tumour sections were stained by immunohistochemistry for Glut-1 and Glut-3. Glut-1 immunostaining revealed that 18 (94.7%) of the 19 tumours stained positively, while Glut-3 immunostaining yielded positive findings for 16 (84.2%) tumours. Overall, a relatively low level of agreement (36.8%) in the staining score was observed between Glut-1 and Glut-3 expression. No relationship was found between the staining pattern and tumour differentiation or T grade classification in either Glut-1 or Glut-3 immunostaining. Furthermore, no relationship was found between increased FDG SUV and tumour differentiation, but the former did correlate with T grade. In conclusion, high FDG uptake values were seen in OSCC with overexpression of Glut-1 and Glut-3. However, no significant correlation was found between FDG SUV and Glut-1 or Glut-3 expression.     

FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values

PURPOSE: FDG uptake mediated by glucose transporter type 1 (Glut-1) and tumor proliferative activity assessed by Ki-67 expression provide prognostic information in patients with non-small-cell lung cancer (NSCLC). Here, we compared the prognostic significances of FDG uptake, and of Glut-1 and Ki-67 expressions in patients with NSCLC. METHODS: NSCLC patients (n=53, F:M=16:37, age 61.9+/-12.1 years) who underwent curative resection after FDG-PET were enrolled. Thirty-one patients had stage I, 15 stage II, and 7 stage III disease. Patients were treated by surgery only (n=12), surgery plus adjuvant oral chemotherapy (n=32), or surgery plus adjuvant intravenous chemo- or radio-therapy (n=9). Maximum standardized FDG uptake values (maxSUV), and the Glut-1 and Ki-67 expressions of resected tumors were analyzed for correlations and relations with tumor recurrence. The median follow-up duration was 15 months. RESULTS: Thirteen (24.5%) of the 53 patients experienced recurrence during a median follow-up of 8 months and significant correlations were found between maxSUV, Glut-1, and Ki-67 expressions (r=0.48-0.79, p<0.001). Univariate analysis revealed that disease-free survival (DFS) was significantly correlated with maxSUV (<7 versus > or =7, p=0.001), % Ki-67 expression (<25% versus > or =25%, p=0.047), tumor size (<3 cm versus > or =3 cm, p=0.027), and tumor cell differentiation (well/moderate versus poor, p=0.011). However, multivariate Cox proportional analysis identified maxSUV as the only determinant of DFS (p=0.005). Patients with a maxSUV of > or =7 (n=14) had a significantly lower 1-year DFS rate (57.1%) than those with a maxSUV of <7 (n=39, 89.7%). CONCLUSION: FDG uptake is more valuable than Glut-1 or Ki-67 expression in terms of predicting prognosis in patients with resected NSCLC.     

肾细胞癌的螺旋CT表现及与病理间的关系

目的　探讨肾细胞癌(RCC)的螺旋CT(SCT)表现及与病理间的关系。资料与方法　搜集行SCT检查并经手术病理证实的RCC 34例,将SCT征象分组与病理征象进行比较。结果　(1) 34例RCC增强后均有显著强化,其中2 6例肿瘤在皮髓期密度等于或超过肾皮质,8例低于肾皮质高于肾髓质;SCT双期增强扫描对34例RCC的检出率为10 0 % ,定性诊断率为10 0 % ,分期的准确性为94 %。(2 )SCT上肿瘤边缘清晰者14例,病理检查12例有完整的假包膜(85 .7% ) ;细胞核分级在瘤体直径>3.0cm组、肿瘤边缘不清晰组、瘤体中心有坏死不强化区组,分别高于瘤体直径≤3.0cm组、肿瘤边缘清晰组、瘤体内无坏死区组(P均<0 .0 1)。结论　SCT双期增强扫描是RCC可靠的检查方法,能准确反映其病理学基础。     

Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer

Purpose

The aim of this study was to determine the relationship between [¹⁸]-2-fluoro-2-deoxy-D-glucose (FDG) uptake and excision repair cross-complementation group 1 (ERCC-1) expression and to evaluate the prognostic effect of these two factors in resectable non-small cell lung cancer (NSCLC) patients.

Methods

We retrospectively reviewed 212 patients with resectable NSCLC who underwent FDG positron emission tomography/computed tomography (PET/CT) scan for cancer staging and ERCC-1 expression analysis between January 2008 to December 2011. All patients were then followed-up for survival analysis. Semiquantitative evaluation of ERCC-1 was performed with the H-scoring system and was correlated with maximum standardized uptake value (SUVmax) of NSCLC. Univariate and multivariate analyses were performed to evaluate for FDG uptake and ERCC-1 expression predicting overall survival.

Results

In 212 patients (139 male, median age 68 ± 9.11), 112 patients had ERCC-positive tumors and 100 patients had ERCC-negative tumors. There was no significant difference in SUVmax between ERCC-1-positive tumors (8.02 ± 5.40) and ERCC-1-negative tumors (7.57 ± 6.56, p = 0.584). All patients were followed-up for a median of 40.5 months (95 % confidence interval [CI], 38.5–42.2 months). Univariate analysis and multivariate analysis for all patients showed that both ERCC-1 expression (hazard ratio [HR], 2.78; 95 % CI, 1.20–6.47) and FDG uptake (HR, 4.50; 95 % CI, 2.07–9.77) independently predicted overall survival.

Conclusions

We have found no statistical correlation between FDG uptake and ERCC-1 expression in NSCLC. However, both higher FDG uptake and positive ERCC-1 expression are independent predictive markers of prognosis, suggesting that both should be obtained during patient workup.     

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy

ObjectiveTo evaluate the radiological tumor response patterns and compare the response assessments based on immune-based therapeutics Response Evaluation Criteria in Solid Tumors (iRECIST) and RECIST 1.1 in metastatic clear-cell renal cell carcinoma (mccRCC) patients treated with programmed cell death-1 (PD-1) inhibitors.Materials and MethodsAll mccRCC patients treated with PD-1 inhibitors at Henan Cancer Hospital, China, between January 2018 and April 2019, were retrospectively studied. A total of 30 mccRCC patients (20 males and 10 females; mean age, 55.6 years; age range, 37–79 years) were analyzed. The target lesions were quantified on consecutive CT scans during therapy using iRECIST and RECIST 1.1. The tumor growth rate was calculated before and after therapy initiation. The response patterns were analyzed, and the differences in tumor response assessments of the two criteria were compared. The intra- and inter-observer variabilities of iRECIST and RECIST 1.1 were also analyzed.ResultsThe objective response rate throughout therapy was 50% (95% confidence interval [CI]: 32.1–67.9) based on iRECIST and 30% (95% CI: 13.6–46.4) based on RECIST 1.1. The time-to-progression (TTP) based on iRECIST was longer than that based on RECIST 1.1 (median TTP: not reached vs. 170 days, p = 0.04). iRECIST and RECIST 1.1 were discordant in 8 cases, which were evaluated as immune-unconfirmed PD based on iRECIST and PD based on RECIST 1.1. Six patients (20%, 6/30) had pseudoprogression based on iRECIST, of which four demonstrated early pseudoprogression and two had delayed pseudoprogression. Significant differences in the tumor response assessments based on the two criteria were observed (p < 0.001). No patients demonstrated hyperprogression during the study period.ConclusionOur study confirmed that the iRECIST criteria are more capable of capturing immune-related atypical responses during immunotherapy, whereas conventional RECIST 1.1 may underestimate the benefit of PD-1 inhibitors. Pseudoprogression is not rare in mccRCC patients during PD-1 inhibitor therapy, and it may last for more than the recommended maximum of 8 weeks, indicating a limitation of the current strategy for immune response monitoring.     

MMP-9在子宫颈鳞状细胞癌中的表达及意义

目的：检测NMP-9在子宫颈鳞状细胞癌中的表达情况,并探讨其与临床病理特征之间的关系。方法：采用免疫组织化学法分别检测MM-9在84例宫颈癌,20例慢性宫颈炎病例中的表达,分析其与临床分期、肿瘤分化程度、淋巴结转移之间的关系。结果：MMP-9在宫颈癌中的阳性表达率为79．8％,显著高于慢性宫颈炎10％（P〈0．05）。在高、中、低分化癌中的阳性表达率分别为52．6％、79．5％、100％,其差异具有统计学意义（P〈0．05）。在TNMI期组中阳性表达率为58．3％,显著低于TNMⅡ期组95．8％（P〈0．05）,在淋巴结转移组阳性率为88％显著高于无淋巴结转移组67．6％（P〈0．05）。结论：在宫颈癌组织中MMP-9呈高表达,MMP-9可能与宫颈癌的浸润转移有关,对判断宫颈癌患者的预后具有一定意义。     

肾透明细胞癌CT分期与PCNA和bcl-2表达的相关性探讨

目的:分析肾透明细胞癌的CT分期与增殖细胞核抗原(PCNA)和bcl 2表达的关系。方法:对51 例经手术病理证实的肾透明细胞癌,采用免疫组化LDP法检测肿瘤标本中PCNA和bcl 2的表达,并对肿瘤进行病理分级,分析其与术前CT分期的关系。结果:PCNA表达与CT分期及病理各分级间具有相关性(P<0.05),在CT分期中Ⅰ期与Ⅲ期、Ⅰ期与Ⅳ期、Ⅱ与Ⅲ期、Ⅱ与Ⅳ期、Ⅰ Ⅱ与Ⅲ Ⅳ期的PCNA表达差异有显著性意义(P<0.05),而bcl 2 表达与肿瘤病理分级及CT分期均无明显相关(P>0.05)。结论:PCNA的表达与肾透明细胞癌的CT分期、病理分级具有相关性,能较为客观、准确的反映肾透明细胞癌的恶性程度,对选择治疗方法有重要的参考价值。     

金属硫蛋白1M在非小细胞肺癌中的表达及其与患者预后的关系

目的 研究金属硫蛋白1M(metallothionein 1M,MT1M)在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达及其与肿瘤侵袭、迁移及预后的关系。方法 购得144对NSCLC组织和对应癌旁组织的组织芯片,采用免疫组织化学方法检测NSCLC组织中MT1M的表达,分析其与NSCLC患者临床病理参数及预后之间的关系;并在体外细胞Transwell功能实验中分析MT1M对NSCLC细胞侵袭和迁移的作用。结果 MT1M在NSCLC组织中的表达明显低于癌旁组织(χ2=143.23,P<0.01),并且NSCLC组织中MT1M的表达与淋巴结转移及TNM分期相关(χ2分别为18.66、12.73,P均<0.01),MT1M抑制NSCLC细胞的侵袭和迁移。结论 MT1M在NSCLC组织中异常低表达,其异常低表达可能与NSCLC患者肿瘤转移相关,并且提示NSCLC患者预后不良。     

IGF-1及其受体在子宫平滑肌瘤中的表达以及与雌、孕激素关系

目的探讨胰岛素样生长因子1(IGF-1)及其受体(IGF-1R)在子宫肌瘤发病中的作用,以及与雌、孕激素的关系。方法采用ELISA方法测定23例子宫肌瘤患者平滑肌瘤、正常子宫平滑肌组织及血清中IGF-1、IGF-1R的表达;同时用E IA方法测定血清雌二醇(E2)、孕酮(P)水平。选择30例健康妇女作为血清指标测定的对照组。结果(1)子宫平滑肌瘤组织IGF-1、IGF-1R的表达较正常子宫平滑肌高(P<0.01)。(2)子宫肌瘤组血清IGF-1表达与对照组无统计学差异(P>0.05):IGF-1R表达较对照组增强(P<0.01)。(3)观察组血清增生期、分泌期E2、P水平均与对照组无统计学差异(P>0.05)。结论子宫平滑肌瘤组织中IGF-1、IGF-1R过度表达可能是子宫肌瘤发生的机制之一,雌、孕激素介导IGF-1对子宫肌瘤的作用,IGF-1对雌、孕激素诱导肌瘤细胞生长、分化主要以自分泌、旁分泌方式在局部起作用,IGF-1可能是子宫肌瘤生长的调节因子。     

FDG PET for grading malignancy in thymic epithelial tumors: Significant differences in FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: Preliminary study

Purpose

To evaluate ¹⁸F-fluorodeoxyglucose (FDG) uptake to predict the malignant nature and analyze the correlation between FDG uptake and expression of glucose transporter 1 (Glut-1) and hexokinase II (HK-II) in thymic epithelial tumors.

Materials and methods

Eleven patients with a thymic epithelial tumor who underwent FDG PET/CT before therapy were reviewed. The thymic tumors were classified by the WHO histological classification and Masaoka clinical staging. Comparison of maximum standardized uptake value (SUV_max) of the lesion was made between the low-risk (Type A, AB and B1) and high-risk {Type B2, B3 and C (thymic cancer)} groups and among clinical stages. Expression of Glut-1 and HK-II was analyzed immunohistochemically.

Results

All 11 tumors showed FDG uptake visually. SUV_max was significantly higher in the high-risk group (n = 5, 5.24 ± 2.44) than the low-risk group (n = 6, 3.05 ± 0.55) (P = 0.008). Staining scores of both Glut-1 and HK-II were significantly higher in the high-risk group than in the low-risk group (Glut1: P = 0.034 and HK-II: P = 0.036). There were no significant differences in SUV_max (P = 0.11), Glut-1 (P = 0.35) and HK-II scores (P = 0.29) among clinical stages. SUV_max was significantly correlated to each of the staining scores of Glut-1 (ρ = 0.68, P = 0.031) and HK-II (ρ = 0.72, P = 0.024).

Conclusion

These preliminary results support the previously published view that SUV_max may be useful to predict the malignant nature of thymic epitherial tumors and suggest that the degree of FDG uptake in the thymic epitherial tumors is closely related to the amount of Glut-1 and HK-II in the tumor.     

COX-1在卵巢癌组织中的表达及其意义

目的探讨环氧化酶-1（COX-1）在卵巢癌组织中的表达及其意义。方法应用免疫组化SP法检测37例卵巢癌和31例卵巢囊肿组织中COX-1和CA125蛋白的表达;应用ELISA法检测40例卵巢癌和31例卵巢囊肿以及60例正常体检者血清中COX-1和CA125的浓度。结果COX-1、CA125在卵巢癌组织的表达率分别为78%和57%,在卵巢囊肿的阳性表达率仅为7%和3%;卵巢癌患者血清COX-1、CA125的阳性率分别为65%和93%。结论COX-1蛋白表达可作为卵巢癌的辅助诊断指标。     

结直肠癌中CD166和TSPAN-1蛋白的表达及其临床意义

目的：观察CD166和TSPAN-1基因在结直肠癌组织中的表达及与临床病理因素的关系。方法：采用免疫组化SP法检测CD166和TSPAN-1蛋白在120例结直肠癌组织、20例结肠腺瘤组织及40例癌旁正常结直肠黏膜组织中的表达。结果：CD166蛋白在正常黏膜、结直肠腺瘤、结直肠癌中阳性率分别为0、20％、55％,组间差异具有统计学意义（P〈0．01）;TSPAN-1蛋白在正常黏膜、结直肠腺瘤、结直肠癌组织中阳性率分别为5％、20％、92％,组间差异均具有统计学意义（P〈0．05）;CD166和TSPAN—1蛋白的表达与结直肠癌的组织学分级及TNM分期有关（P〈0．01）;CD166和TSPAN-1在结直肠癌组织中的表达强度呈正相关（r=0．524,P〈0．001）。二者表达完全一致率高达36．7％（44／120）。结论：CD166和TSPAN—1基因的高表达与结直肠癌的侵袭和发展有关,两者在结直肠癌的细胞增殖、浸润和转移中具有协同作用。联合检测两者的表达对于进一步理解结直肠癌的生物学行为和判断预后有一定价值。     

BOLD-MRI评价肾透明细胞癌HIF-α表达的可行性研究

目的 评价透明细胞肾癌(CRCC) R2*值变化与肿瘤组织内缺氧诱导因子(HIF-1α、HIF-2α)表达的相关性.方法 回顾性分析26例经手术病理证实的CRCC患者血氧水平依赖MRI与HIF-1α、HIF-2α的结果.使用Furhman法划分肿瘤的病理级别,并将所有患者分成低级别和高级别两个亚组.测量所有患者肿瘤实质的R2*值.比较高低级别组CRCC之间HIF-1 α、HIF-2α表达情况的差异.使用Pearson相关分析法评价R2*值与HIF-α阳性表达率之间的关系.结果 低级别组(Ⅰ+Ⅱ)17例,高级别组(Ⅲ+Ⅳ)9例.高级别组R2*值明显高于低级别组(P ＜0.005).高级别组HIF-α阳性表达率值明显高于低级别组(P＜0.05).CRCC的R2*值与HIF-2α表达与组织的R2*值呈正相关(P＜0.05).结论 R2*值作为一种无创的评价指标有助于CRCC的病理核分级,且R2*值与HIF-2α表达水平存在相关性.